Risk of Regulatory Changes in Regenerative Medicine and Drug Discovery
First written in FY2018. 4 of 5 entries say "Restated". Latest entry: FY2026.
0 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「This could affect the business and financial results of our Group.」
The company continues to hold the same view as before regarding the risk of changes in laws and regulations concerning regenerative medicine, drug discovery and related fields. - FY2022RestatedAnnual report
「If government policies result in major revisions to relevant laws and regulations, or if research and development activities are restricted by laws and regulations, this could affect the business and financial results of our Group.」
The risks of revisions to laws and regulations and restrictions on research and development concerning regenerative medicine and drug discovery continue to be disclosed. - FY2020RestatedAnnual report
「If government policies result in major revisions to relevant laws and regulations, or if research and development activities are restricted by laws and regulations, this could affect our business and financial results.」
Revisions to laws and regulations and restrictions on research and development in the regenerative medicine and drug discovery fields continue to be identified as risks. - FY2019RestatedAnnual report
「If government policies result in major revisions to relevant laws and regulations, or if research and development activities are restricted by laws and regulations, this could affect our business and financial results.」
Revisions to laws and regulations and restrictions on research and development concerning regenerative medicine and drug discovery continue to be identified as risks. - FY2018First statedAnnual report
「If government policies result in major revisions to relevant laws and regulations, or if research and development activities are restricted by laws and regulations, this could affect our business and financial results.」
Revisions to laws and regulations and restrictions on research and development concerning iPS cells, regenerative medicine and drug discovery are disclosed as risks.